Loss of BMP2, Smad8, and Smad4 Expression in Prostate Cancer Progression

Prostate

Volumn 59, Issue 3, 2004, Pages 234-242

  Horvath, Lisa G ^a   Henshall, Susan M ^a   Kench, James G ^a,b   Turner, Jennifer J ^a   Golovsky, David ^a   Brenner, Phillip C ^a   O'Neill, Gordon F ^a   Kooner, Raji ^a   Stricker, Phillip D ^a   Grygiel, John J ^a   Sutherland, Robert L ^a,c  

^a ST VINCENT S HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

BMP2; Prostate cancer; Radical prostatectomy; Smad4; Smad8

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; SMAD4 PROTEIN; SMAD8 PROTEIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; HUMAN; HUMAN TISSUE; HYPERPLASIA; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BONE MORPHOGENETIC PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; COHORT STUDIES; DISEASE PROGRESSION; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; SMAD8 PROTEIN; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 11144355740     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10361     Document Type: Article

References (45)

1. Tracey EA, Supramaniam R. Cancer in New South Wales: Incidence and mortality 2000 featuring projections to 2010 for selected sites. Sydney: The Cancer Council NSW; 2002.
2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
3. Chung LWK, Isaacs WB, Simons JW. Prostate cancer: Biology, genetics, and the new therapeutics. Totowa, New Jersey: Humana Press; 2001.
4. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.
5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegrom M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 2001;344:783-792.
6. Kawabata M, Imamura T, Miyazono K. Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev 1998;9:49-61.
7. von Bubnoff A, Cho KWY. Intracellular BMP signalling regulation in vertebrates: Pathway of network? Dev Biol 2001;239: 1-14.
8. Moustakas A, Souchelnytskyi S, Heldin CH. Smad regulation in TGFβ signal transduction. J Cell Sci 2001;114:4359-4369.
9. Piek E, Heldin CH, ten Dijke P. Specificity, diversity, and regulation in TGF-β superfamily signaling. FASEB 1999;13: 2105-2124.
10. Bentley H, Hamdy FC, Hart KA, Seid JM, Williams JL, Johnstone D, Russell RGG. Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1992;66:1159-1163.
11. Hamdy FC, Autzen P, Robinson MC, Horne CHW, Neal DE, Robson CN. Immunolocalization amd messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Cancer Res 1997;57:4427-4431.
12. Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI, Neal DE, Hamdy FC. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer 1998;78:1219-1223.
13. Masuda H, Fukabori Y, Nakano K, Takezawa Y, CSuzuki T, Yamanaka H. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 2003;54: 268-274.
14. Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y, Sugimura T, Terada M. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 1997;57:5022-5027.
15. Ide H, Katoh M, Sasaki H, Yoshida T, Aoki K, Nawa Y, Osada Y, Sugimura T, Terada M. Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and its expression in prostate cancer in comparison with other BMPRs. Oncogene 1997;14: 1377-1382.
16. Kim IY, Lee DH, Ahn HJ, Tokunaga H, Song W, Devereaux LM, Jin D, Sampath TK, Morton RA. Expression of bone morphogenetic protein receptors type-IA, -IB, and -II correlates with tumor grade in human prostate cancer tissues. Cancer Res 2000;60: 2840-2844.
17. Henshall SM, Afar DEH, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher H, Grygiel JJ, Agus DB, Mack DH, Sutherland RL. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 2003;63:4196-4203.
18. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihiatsch MJ, Sauter G, Kallioniemi O-P. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
19. McNeal JE. Prostate. In: Sternberg SS, editor. Histology for pathologists. Philadelphia/New York: Lippincott-Raven; 1997. pp 997-1018.
20. Nishita M, Ueno N, Shibuya H. Smad8B, a Smad8 splice variant lacking the SSXS site that inhibits Smad8-mediated signalling. Genes Cells 1999;4:583-591.
21. Watanabe TK, Suzuki M, Omori Y, Hishigaki H, Horie M, Kanemoto N, Fujiwara T, Nakamura Y, Takahashi E. Cloning and characterization of a novel member of the human Mad gene family (MADH6). Genomics 1997;42:446-451.
22. Biankin AV, Morey AL, Lee CS, Kench JG, Biankin SA, Hook HC, Head DR, Hugh TB, Sutherland RL, Henshall SM. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol 2002;20:4531-4542.
23. Quinn DI, Henshall SM, Head DR, Golovsky D, Wilson JD, Brenner PC, Turner JJ, Delprado W, Finlayson JF, Grygiel JJ, Stricker PD, Sutherland RL. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res 2000;1585-1594.
24. Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, Makela S, Delprado W, Golovsky D, Brenner PC, O'Neill G, Kooner R, Stricker PD, Grygiel JJ, Gustafsson JA, Sutherland RL. Frequent loss of estrogen receptor-β expression in prostate cancer. Cancer Res 2001;61:5331-5335.
25. Henshall SM, Afar DEH, Rasiah KK, Horvath LG, Gish K, Caras I, Ramakrishnan V, Wong M, Jeffry U, Kench JG, Quinn DI, Turner JJ, Delprado W, Lee C-S, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Mack DH, Sutherland RL. Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene 2003;22:6005-6012.
26. Quinn DI, Henshall SM, Haynes AM, Brenner PC, Kooner R, Golovsky D, O'Neill G, Turner JJ, Delprado W, Finlayson JF, Sutherland RL, Grygiel JJ, Stricker PD. Prognostic significance of pathological features in localized prostate cancer treated with radical prostatectomy: Implications for staging systems and predictive models. J Clin Oncol 2001;19:3692-3705.
27. Yamamoto T, Saatcioglu F, Matsuda T. Cross-talk between bone morphogenetic proteins and estrogen receptor signaling. Endocrinology 2002;143:2635-2642.
28. Pouliot F, Labrie C. Role of Smad1 and Smad4 proteins in the induction of p21WAF1,Cip1 during bone morphogenetic protein-induced growth arrest in human breast cancer cells. J Endocrinol 2002;172:187-198.
29. Soda H, Raymond E, Sharma S, Lawrence R, Cerna C, Gomez L, Timony GA, Von Holff DD, Izbicka E. Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units. Anti-cancer Drugs 1998;9:327-331.
30. Kleef J, Maruyama H, Ishiwata T, Sawhey H, Friess H, Buchler MW, Kore M. Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology 1999;116:1202-1216.
31. Sulzbacher I, Birner P, Trieb K, Pichlbauer E, Lang S. The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter. J Clin Pathol 2002;55: 381-385.
32. Itoh S, Itoh F, Goumans MJ, ten Dijke P. Signaling of transforming growth factor-β family members through Smad proteins. Eur J Biochem 2000;267:6954-6967.
33. Barnes J, Anthony CT, Wall N, Steiner MS. Bone morphogenetic protein-6 expression in normal and malignant prostate. World J Urol 1995;13:337-343.
34. Harris SE, Harris MA, Mahy P, Wozney J, Feng JQ, Mundy GR. Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 1994;24:204-211.
35. MacGrogan D, Pegram M, Slamon D, Bookstein R. Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene 1997;15:1111-1114.
36. Brodin G, ten Dijke P, Funa K, Heldin CH, Landstrom M. Increased Smad expression and activation are associated with apoptosis in normal and malignant prostate after castration. Canc Res 1999;59:2731-2738.
37. Truong LD, Kadmon D, McCune BK, Fladers KC, Scardino PT, Thompson TC. Assocuation of transforming growth factor-beta1 with prostate cancer: An immunohistochemical study. Hum Pathol 1993;24:4-9.
38. Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT, Thompson TC. Transforming growth factor-beta 1: Comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 1995;73: 628-635.
39. Shariat SF, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, Wheeler TM, Slawin KM. Preoperative plasma levels of transforming growth factor beta1 (TGFβ) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 2001;19:2856-2864.
40. Matthews E, Yang T, Janulis L, Goodwin S, Kundu SD, Karpus WJ, Lee C. Down-regulation of TGF-β1 production restores immunogenicity in prostate cancer cells. Br J Cancer 2000;83:519-525.
41. Williams RH, Stapleton AMF, Yang G, Truong LD, Rogers E, Timme TL, Wheeler TM, Scardino PT, Thompson TC. Reduced levels of transforming growth factor receptor β type II in human prostate cancer: An immunohistochemical study. Clin Cancer Res 1996;2:635-640.
42. Chipuk JE, Cornelius SC, Pultz NJ, Jorgensen JS, Bonham MJ, Kim S-J, Danielpour D. The androgen receptor represses transforming growth factor-β signaling through interaction with Smad3. J Biol Chem 2002;277:1240-1248.
43. Kang HY, Lin HK, Hu YC, Yeh S, Huang KE, Chang C. From transforming growth factor-β signaling to androgen action: Identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc Natl Acad Sci USA 2001;98: 3018-3023.
44. Kang HY, Huang KE, Chang SY, Ma WL, Lin WL, Chang C. Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4. J Biol Chem 2002;277:43749-43756.
45. ten Dijke P, Goumans M-J, Itoh F, Itoh S. Regulation of cell proliferation by smad proteins. J Cell Physiol 2002;191:1-16.